New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy administered as a single infusion, in the treatment of patients with relapsed and/or refractory multiple myeloma. The data, featured as an oral presentation at the American Society of Hematology (ASH) 2021 Annual Meeting (Abstract #549) and selected as part of the Highli...
Source: Johnson and Johnson - December 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Isatuximab Added to RVd Boosts Response in New Myeloma Isatuximab Added to RVd Boosts Response in New Myeloma
The addition of the anti-CD38 antibody improved minimal residual disease rates at the end of induction, a marker for better outcomes following autologous stem cell transplant.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC) Pha...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Clinical and Real-World Data Support Use of DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone (Rd). Updated data from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients were presented at the American Society of Hematology (ASH) 2021 Annual Meeting. Data from the GRIFFIN study will also be featured...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
US Oncology Research, The US Oncology Network and Ontada Announce Data Presentations across Areas of Critical Need at 2021 American Society of Hematology Annual Meeting and Exposition
THE WOODLANDS, Texas, Dec. 9, 2021 — Investigators from US Oncology Research, The US Oncology Network (The Network), and OntadaTM will share results from more than 30 studies exploring areas such as diffuse large B cell lymphoma, non-Hodgkin lymphoma, multiple myeloma and hematological adverse even... (Source: McKesson News)
Source: McKesson News - December 9, 2021 Category: Information Technology Source Type: news
